Brief reports
Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion

https://doi.org/10.1016/j.amjcard.2003.12.009Get rights and content

Abstract

To test the hypothesis that a statin could reduce the recurrence rate of atrial fibrillation after electrical cardioversion (EC), we performed an open, controlled multicenter study. Patients (n = 114) who had atrial fibrillation >48 hours and who were scheduled for EC were randomized to receive 40 mg of pravastatin once daily for 3 weeks before and 6 weeks after EC or no drug in addition to standard therapy. Pravastatin did not reduce the recurrence rate of atrial fibrillation after EC.

References (12)

There are more references available in the full text version of this article.

Cited by (125)

  • A new score for detection of early cardioversion using intravenous amiodarone in recent onset atrial fibrillation

    2016, Egyptian Heart Journal
    Citation Excerpt :

    Our analysis did not confirm a correlation between the time of amiodarone cardioversion and dyslipidemia, and the intake of statins had no statistically significant difference in the time of cardioversion. Despite the results of Tveit et al.17 suggest that lipid-lowering drug use is associated with a significant reduction in AF risk, the role of lipid-lowering drugs in the treatment of preexisting AF is not elucidated by this study and remains controversial. In this study we found that smoking has no significant effect on time of amiodarone cardioversion.

  • The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions: A systematic review and meta-analysis

    2013, International Journal of Cardiology
    Citation Excerpt :

    The studies were homogeneous (I2 = 31% and p = 0.14 for heterogeneity). Among the RCTs four out of eleven trials were categorized as having high potential risk of bias [17,30,31,38]. Assessing exclusively the 16 observational studies, statin treatment showed a significant risk reduction (RR: 0.813 [95%CI: 0.79–0.83], p < 0.001).

View all citing articles on Scopus

This study was supported by Bristol-Myers Squibb Norway Ltd., Oslo, Norway, whose support covered all costs of the study medication.

View full text